The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Rare Disease Diagnostics Market Projected To Reach By 2030?
The rare disease diagnostics market has experienced significant expansion recently. This market is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. Historical expansion has been driven by factors such as the broader availability of genetic testing, enhanced recognition of rare diseases among medical professionals, the expanded application of molecular diagnostics, the proliferation of specialized diagnostic laboratories, and better access to sophisticated imaging technologies.
The rare disease diagnostics market size is anticipated to undergo significant growth in the coming years. Its value is projected to climb to $62.18 billion in 2030, displaying a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period can be attributed to the wider adoption of personalized medicine, increasing investments in genomics research, a rising need for early-stage rare disease detection, the greater integration of AI-driven diagnostic tools, and the broadening of rare disease screening programs. Noteworthy trends in the forecast period encompass the increasing embrace of next-generation sequencing diagnostics, a growing utilization of multi-gene panel testing, the expanding integration of advanced imaging in rare disease diagnosis, the establishment of more centralized rare disease testing centers, and a heightened focus on early and accurate diagnosis.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp
Which Key Factors Are Driving The Rare Disease Diagnostics Market Growth?
A rise in the occurrence of rare diseases is projected to drive the expansion of the rare disease diagnostics market in the future. These conditions are health issues impacting a minor segment of the populace compared to widespread illnesses, frequently necessitating specialized diagnostic instruments for prompt and precise identification. Diagnostics for rare diseases contribute to better disease management, facilitate the discovery of potential therapies, and minimize needless or detrimental treatments, ultimately fostering more effective patient care. As an example, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current scope of rare kidney diseases encompasses more than 150 distinct conditions, impacting approximately 70 per 100,000 people, primarily stemming from genetic changes. Consequently, the growing frequency of rare diseases is fueling the expansion of the rare disease diagnostics market.
How Is The Rare Disease Diagnostics Market Organized By Segment Classification?
The rare disease diagnostics market covered in this report is segmented –
1) By Test Type: Genetic Test, General Lab Test, Imaging Test
2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays
3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva
4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease
5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories
Subsegments:
1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing
2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests
3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays
Which Trends Are Guiding The Direction Of The Rare Disease Diagnostics Market?
Leading companies in the rare disease diagnostics market are prioritizing the development of advanced solutions, such as high-sensitivity whole genome sequencing (WGS) platforms. Their goal is to enhance diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. High-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thus facilitating earlier and more accurate diagnoses. For example, in April 2023, Centogene GmbH, a rare disease company from Germany, introduced CentoGenome. This enhanced next-generation sequencing (NGS)-based whole genome sequencing solution is tailored for the diagnosis of rare and neurodegenerative diseases. The platform provides broad variant coverage, which includes Copy Number Variations (CNVs) linked to spinal muscular atrophy (SMA) and intricate pathogenic variants associated with Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome integrates PCR-free technology to minimize sequencing bias in challenging genomic regions. This feature ensures higher-quality data and deeper insights into coding, regulatory, and intronic areas, thereby supporting more precise clinical interpretation.
Who Are The Industry Participants Involved In The Rare Disease Diagnostics Market?
Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.
Get The Full Rare Disease Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Which Region Leads The Rare Disease Diagnostics Market In Overall Market Size?
North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Rare Disease Diagnostics Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company
Rare Disease Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Rare Diseases Treatment Market Report
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model